Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 4881 participants.
Also called NCT00991029
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 4,881 participants
- Registry
-
NCT00991029
-
- Other papers using this trial's data
- Association of Black Race With Early Recurrence After Minor Ischemic Stroke or Transient Ischemic Attack: Secondary Analysis of the POINT Randomized Clinical Trial
- Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA
- Observed Versus Predicted Stroke Risk After Transient Ischemic Attack: A Post Hoc Analysis of a Randomized Clinical Trial
- Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial
- Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke
- Time to treatment and disability attributed to index stroke in the POINT trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Finland, France, Germany, Mexico, New Zealand, Spain, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT00991029. Randomized; double masking; primary purpose treatment. Start 2010-05-28 (actual); primary completion 2018-04-09 (actual). Results posted on 2018-12-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
- Acronym
- POINT
- Condition
- Ischemic Attack, Transient
- Intervention (Drug)
- Clopidogrel
- Intervention (Drug)
- placebo
- Lead sponsor
- University of California, San Francisco
- Collaborator
- Neurological Emergencies Treatment Trials Network (NETT)
- Collaborator
- Medical University of South Carolina
- Collaborator
- The Emmes Company, LLC
Record details
- Record id
cardio:ct-nct00991029- Content hash
7f6181388ac552ea12b48b7fa0884d645825481a20ca0dc19f005ea857f75166